Drug Profile
NOX 200
Latest Information Update: 16 Aug 2002
Price :
$50
*
At a glance
- Originator Medinox
- Class Antihyperglycaemics; Antirheumatics; Small molecules
- Mechanism of Action Nitric oxide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis; Type 1 diabetes mellitus
Most Recent Events
- 19 Oct 1998 New profile
- 19 Oct 1998 Preclinical development for Rheumatoid arthritis in USA (PO)
- 19 Oct 1998 Preclinical development for Type-1 diabetes mellitus in USA (PO)